Login / Signup

PMS2 monoallelic mutation carriers: the known unknown.

McKinsey L GoodenbergerBrittany C ThomasDouglas Riegert-JohnsonC Richard BolandSharon E PlonMark ClendenningAung Ko WinLeigha SenterSteven M LipkinZsofia K StadlerFinlay A MacraeHenry T LynchJeffrey N WeitzelAlbert de la ChapelleSapna SyngalPatrick LynchSusan ParryMark A JenkinsSteven GallingerSpring HolterMelyssa AronsonPolly A NewcombTerrilea BurnettLoïc Le MarchandPavel PichurinHeather HampelJonathan P TerdimanKaren H LuStephen ThibodeauNoralane M Lindor
Published in: Genetics in medicine : official journal of the American College of Medical Genetics (2015)
Germ-line mutations in MLH1, MSH2, MSH6, and PMS2 have been shown to cause Lynch syndrome. The penetrance of the cancer and tumor spectrum has been repeatedly studied, and multiple professional societies have proposed clinical management guidelines for affected individuals. Several studies have demonstrated a reduced penetrance for monoallelic carriers of PMS2 mutations compared with the other mismatch repair (MMR) genes, but clinical management guidelines have largely proposed the same screening recommendations for all MMR gene carriers. The authors considered whether enough evidence existed to propose new screening guidelines specific to PMS2 mutation carriers with regard to age at onset and frequency of colonic screening. Published reports of PMS2 germ-line mutations were combined with unpublished cases from the authors' research registries and clinical practices, and a discussion of potential modification of cancer screening guidelines was pursued. A total of 234 monoallelic PMS2 mutation carriers from 170 families were included. Approximately 8% of those with colorectal cancer (CRC) were diagnosed before age 30, and each of these tumors presented on the left side of the colon. As it is currently unknown what causes the early onset of CRC in some families with monoallelic PMS2 germline mutations, the authors recommend against reducing cancer surveillance guidelines in families found having monoallelic PMS2 mutations in spite of the reduced penetrance.Genet Med 18 1, 13-19.
Keyphrases